Hong-Wu Chen[Author] - Search Results

Year	Number of Results
2002	1
2003	3
2004	2
2006	4
2007	2
2008	2
2009	4
2010	10
2011	3
2012	4
2013	6
2014	3
2015	4
2016	7
2017	2
2018	4
2019	8
2020	8
2021	4
2022	8
2023	4
2024	1

1

Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion.

Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, Hamsafar Y, Evans AC, Huang J, Zhou W, Lin X, Ye N, Wanggou S, Chen W, Jing D, Fragoso RC, Dugger BN, Wilson PF, Coleman MA, Xia S, Li X, Sun LQ, Monjazeb AM, Wang A, Murphy WJ, Kung HJ, Lam KS, Chen HW, Li JJ. Jiang N, et al. Among authors: chen hw. Nat Commun. 2022 Mar 21;13(1):1511. doi: 10.1038/s41467-022-29137-3. Nat Commun. 2022. PMID: 35314680 Free PMC article.

2

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype.

Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, Xu J, Jiang Y, Zou H, Huang Z, Borowsky AD, Bold RJ, Lara PN, Li JJ, Chen X, Lam KS, To KF, Kung HJ, Fiehn O, Zhao R, Evans RM, Chen HW. Cai D, et al. Among authors: chen hw. Nat Commun. 2019 Oct 11;10(1):4621. doi: 10.1038/s41467-019-12529-3. Nat Commun. 2019. PMID: 31604910 Free PMC article.

3

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.

Xu P, Yang JC, Chen B, Nip C, Van Dyke JE, Zhang X, Chen HW, Evans CP, Murphy WJ, Liu C. Xu P, et al. Among authors: chen hw. J Immunother Cancer. 2023 May;11(5):e006581. doi: 10.1136/jitc-2022-006581. J Immunother Cancer. 2023. PMID: 37147019 Free PMC article.

4

Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via NRF2 in cancer therapeutic resistance.

Wang H, Wang Q, Cai G, Duan Z, Nugent Z, Huang J, Zheng J, Borowsky AD, Li JJ, Liu P, Kung HJ, Murphy L, Chen HW, Wang J. Wang H, et al. Among authors: chen hw. Acta Pharm Sin B. 2022 Apr;12(4):1871-1884. doi: 10.1016/j.apsb.2021.10.015. Epub 2021 Oct 21. Acta Pharm Sin B. 2022. PMID: 35847493 Free PMC article.

5

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.

Chen Y, Tu MJ, Han F, Liu Z, Batra N, Lara PN, Chen HW, Bi H, Yu AM. Chen Y, et al. Among authors: chen hw. Acta Pharm Sin B. 2023 Oct;13(10):4273-4290. doi: 10.1016/j.apsb.2023.07.011. Epub 2023 Jul 15. Acta Pharm Sin B. 2023. PMID: 37799388 Free PMC article.

6

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer.

Huang JL, Yan XL, Huang D, Gan L, Gao H, Fan RZ, Li S, Yuan FY, Zhu X, Tang GH, Chen HW, Wang J, Yin S. Huang JL, et al. Among authors: chen hw. Acta Pharm Sin B. 2023 Dec;13(12):4934-4944. doi: 10.1016/j.apsb.2023.07.017. Epub 2023 Jul 24. Acta Pharm Sin B. 2023. PMID: 38045040 Free PMC article.

7

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. Wang J, et al. Among authors: chen hw. Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070. Epub 2016 Mar 28. Nat Med. 2016. PMID: 27019329 Free PMC article.

8

Nuclear receptor RORγ inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy.

Zou H, Yang Y, Shi Z, Wu X, Liu R, Yu AM, Chen HW. Zou H, et al. Among authors: chen hw. Pharmacol Res. 2022 Aug;182:106324. doi: 10.1016/j.phrs.2022.106324. Epub 2022 Jun 21. Pharmacol Res. 2022. PMID: 35750301 Free PMC article.

9

Nuclear receptor coregulators as a new paradigm for therapeutic targeting.

Hsia EY, Goodson ML, Zou JX, Privalsky ML, Chen HW. Hsia EY, et al. Among authors: chen hw. Adv Drug Deliv Rev. 2010 Oct 30;62(13):1227-37. doi: 10.1016/j.addr.2010.09.016. Epub 2010 Oct 7. Adv Drug Deliv Rev. 2010. PMID: 20933027 Free PMC article. Review.

10

RORγ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases.

Zou H, Yang N, Zhang X, Chen HW. Zou H, et al. Among authors: chen hw. Biochem Pharmacol. 2022 Feb;196:114725. doi: 10.1016/j.bcp.2021.114725. Epub 2021 Aug 9. Biochem Pharmacol. 2022. PMID: 34384758 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year